Dermata Therapeutics, Inc.
DRMAW
NASDAQ Capital Market0.01
USD
+0.00
- -
CIK
0001853816
ISIN
US2498451168
CUSIP
249845116
Return %
Stock
S&P500
1Y
-26.11
19.01
3Y
-53.28
65.48
5Y
-98.95
72.20
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Gerald T. Proehl
- Full Time Employees
- 9
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 3525 Del Mar Heights Road San Diego CA United States of America 92130
- IPO Date
- Aug 13, 2021
- CIK
- 0001853816
- Website
- dermatarx.com
- Similar Companies
- Business
- Dermata Therapeutics, Inc. (Nasdaq: DRMA) is a clinical-stage biotechnology company that develops and commercializes topical pharmaceutical product candidates derived from its proprietary Spongilla platform technology for the treatment of medical skin diseases including moderate-to-severe acne, mild-to-moderate psoriasis, papulopustular rosacea, hyperhidrosis, and aesthetic skin conditions. The company's lead product candidate, XYNGARI (formerly DMT310), a once-weekly topical treatment sourced from Spongilla lacustris freshwater sponge with anti-inflammatory, anti-microbial, and mechanical properties, advances through Phase 3 clinical trials (STAR-1 and STAR-2) for acne and has demonstrated positive data from prior Phase 2b studies; DMT410 employs the Spongilla technology to facilitate topical intradermal delivery of macromolecules such as botulinum toxin for hyperhidrosis and aesthetic applications following completed Phase 1b proof-of-concept trials; DMT400 represents a combination regimen for enhanced dermal delivery of biologics in psoriasis, acne, rosacea, and cosmetics. In September 2025, Dermata announces a strategic pivot from prescription dermatology to over-the-counter (OTC) pharmaceutical products leveraging Spongilla with active ingredients for direct-to-consumer markets in acne, psoriasis, and seborrheic dermatitis, including development of an initial once-weekly acne kit slated for mid-2026 launch. Additional recent developments encompass a January 2025 clinical trial collaboration agreement with Revance Therapeutics, Inc. to evaluate XYNGARI with DAXXIFY for axillary hyperhidrosis; $6.2 million in warrant exercise proceeds in March 2025 and $2.55 million private placement in January 2025 to fund operations; FDA approval of the XYNGARI brand name and a new acne treatment patent in late 2024; and $8.8 million raised via private placements and warrant financings in the first half of 2025. Founded in 2014 and headquartered in San Diego, California, Dermata targets the U.S. dermatology market exceeding $8.3 billion, with ongoing discussions for partnerships in botulinum toxin delivery and potential pipeline expansions through licensing or acquisitions.
A New Realm of Skincare is Coming: Dermata Teases New OTC Brand Identity